The prognosis for patients with malignant brain tumors remains grim despite advances in neurosurgery, radiation treatment, neuroimaging and chemotherapy. Clinical studies are needed to evaluate new treatment approaches. Laboratory research is required to provide the foundation for future therapies. The creation of a consortium, bringing together a multidisciplinary team of clinical and laboratory researchers and pooling the resources of several centers, will facilitate and enhance these needed studies. This proposal describes the resources available at the Pittsburgh Cancer Institute (PCI), University of Pittsburgh, qualifying it for participation in the Central Nervous System Consortium (CNSC). The Central Operations Office/Coordinating Center for this consortium will be at the University Of California, San Francisco. The resources of the PCI, including the Clinical Core Facility and the Tissue Bank, will provide essential support for CNSC-related trials. The PC Brain Tumor Center, with its clinical and laboratory investigators dedicated to advancing the treatment of brain tumor patients, will collaborate with other members of the CNSC to rapidly evaluate new treatments and investigate avenues of translational research. Initial studies will involve evaluating new agents, including taxol and temozolomide, in the treatment of malignant gliomas. Future investigations may include using inhibitors of O6-alkyl guanine DNA transferase to modulate tumor resistance to nitrosoureas, examining other investigational agents, and evaluating new drug delivery systems. Ongoing laboratory studies include exploring modulators of drug resistance, in vitro chemotherapy sensitivity assays, differentiation agents in brain tumor therapy, mechanisms of brain tumor invasiveness, and cytogenetic and molecular correlates of treatment response and prognosis. Advances in these projects will lead to innovative treatments that may be suitable for testing in the CNSC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA062405-02
Application #
2103614
Study Section
Special Emphasis Panel (SRC (68))
Project Start
1994-03-18
Project End
1997-12-31
Budget Start
1995-01-01
Budget End
1995-12-31
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Vivanco, Igor; Robins, H Ian; Rohle, Daniel et al. (2012) Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2:458-71
Norden, Andrew D; Raizer, Jeffrey J; Abrey, Lauren E et al. (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96:211-7
Raizer, Jeffrey J; Abrey, Lauren E; Lassman, Andrew B et al. (2010) A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 12:95-103
Raizer, Jeffrey J; Abrey, Lauren E; Lassman, Andrew B et al. (2010) A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol 12:87-94
Chang, Susan M; Lamborn, Kathleen R; Kuhn, John G et al. (2008) Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol 10:631-42
Lamborn, Kathleen R; Yung, W K Alfred; Chang, Susan M et al. (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162-70
Prados, Michael D; Yung, W K A; Wen, Patrick Y et al. (2008) Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol 61:1059-67
Groves, Morris D; Puduvalli, Vinay K; Chang, Susan M et al. (2007) A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 81:271-7
Cloughesy, Timothy F; Wen, Patrick Y; Robins, H Ian et al. (2006) Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 24:3651-6
Cloughesy, Timothy F; Kuhn, John; Robins, H Ian et al. (2005) Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 23:6647-56

Showing the most recent 10 out of 17 publications